结果1 题目 Current new weight-loss drugs are not ___ for long-term use because they can give greater weight loss with more side effects. 该题您未回答:х 该问题分值: 1 相关知识点: 试题来源: 解析 答案:suitable 反馈 收藏
With Novo Nordisk's Semaglutide "leading the charge" in the weight loss field, more and more weight loss drugs are coming into public view, some of which have weight loss effects that are not inferior to Semaglutide and Tirzepatide, such as Retatrutide developed by Lilly and Mashiduo peptid...
A comprehensive review of the literature was conducted using multiple databases, including PubMed, MEDLINE, and Ovid. Keywords used to obtain relevant articles included obesity and drug, or...doi:10.1002/pdi.2044Kate MillarRuth PooleJohn Wiley & Sons, Ltd.Practical Diabetes...
33). As a result, the development of effective drugs with acceptable side-effects can be very cumbersome. With respect to durable weight reduction, bariatric surgery is the most effective long-term treatment for severe obesity with the greatest chances for amelioration and even resolution of obesity...
Continuous clinical and preclinical studies on existing and potential drugs are needed to improve treatment of nonalcoholic fatty liver disease/NASH. 展开 关键词: NASH Pharmacologic therapy Weight loss Lifestyle modification Insulin sensitizers Fatty acids Antioxidants ...
current as it measures the increase in the current of the anode due to coupling with the cathode. As large differences betweencorrosion ratesas determined by weight loss and galvanic current have been observed, it may be simpler to use traditional weight loss techniques (Baboian et al., 1974)...
https://www.fda.gov/drugs/developmentapprovalprocess/default. htm (2018). Accessed 23 Dec 2019. Grazul H, Kanda LL, Gondek D. Impact of probiotic supplements on microbiome diversity following antibiotic treatment of mice. Gut Microbes. 2016;7:101–14. PubMed PubMed Central Google Scholar ...
As for health food-drug interactions, an important pharmacokinetic interaction between drugs and St. John's Wort was described from several viewpoints: different effects on drugs within the same class (depending on the metabolic pathway); interindividual differences in its effects; importance of ...
Burger AJ, Charlamb MJ, Singh S, et al. Low risk of significant echocardiographic valvulopathy in patients treated with anorectic drugs.Int J Cardiol.2001;79(2–3):159–65. ArticlePubMedCASGoogle Scholar Rossi M, Kim MS, Morgan DGA, et al. A C-terminal fragment of agouti-related protei...
Since its FDA approval in 2012, lorcaserin (Belviq®) was one of the most frequently prescribed weight-loss drugs until early 2020. However, lorcaserin did not gain an approval from the European Medical Agency (EMA), as its preclinical data revealed the potential risk of breast cancer, psychi...